China will tighten the inspection of pharmaceutical products to prevent drug
safety accidents, the country's drug watchdog said Tuesday, disclosing that the
licenses of 353 medicines have been revoked since August 2006.
Zhen, deputy director of the State Food and Drug Administration (SFDA), said
about 3,049 applications for producing new drugs were turned down since last
August to fend off shoddy manufacture of medicines.
Attending an online interview hosted by the central government's website, Wu
said the administration has required its officials to leave offices to check
whether the production conditions meet the description of the applications filed
to the SFDA.
"For those that fail to reach the standards, the administration will return
the applications or have their licenses revoked," Wu said.
He said the administration in the previous year "effectively" handled 14
large-scale health hazard cases caused by bogus drugs, including the case of
Qiqihar fake Armillarisin A injection that killed eleven people and the case of
Xinfu antibiotic that killed at least ten.
Another 17 health accidents concerning shoddy medicine facilities were
Wu said this year will be a critical year in improving drugs production
supervision, with the ambitious goal to eliminate major health crisis caused by
problematic food and drugs.
"The task for all SFDA staff is arduous; the responsibilities are big. But we
are confident to take good care of the work," Wu said.
In late January, China made an investigation into allegations of former SFDA
chief Zheng Xiaoyu for abusing his power to take bribes while ignoring drug